Introduction {#s1}
============

Common diseases such as type 2 diabetes are highly phenotypically heterogeneous. Few studies have performed genome wide association studies in subsets of patients defined by more stringent phenotypic characteristics. It is possible that reducing the heterogeneity of disease cases may increase power to detect associations over and above the loss of power resulting from reduced numbers. To address these questions we hypothesized that the genetic predisposition to Type 2 diabetes may be different in two strata of cases defined by well-accepted cut-offs for body mass index, the strongest known risk factor for type 2 diabetes.

Genome-wide association (GWA) studies have identified ∼50 independent loci robustly associated with type 2 diabetes [@pgen.1002741-Voight1], [@pgen.1002741-Dupuis1], [@pgen.1002741-Qi1], [@pgen.1002741-Tsai1], [@pgen.1002741-Yamauchi1], [@pgen.1002741-Shu1], [@pgen.1002741-Kooner1]. These studies have highlighted new candidate pathways involved in the disease [@pgen.1002741-Lyssenko1], [@pgen.1002741-Prokopenko1], identified overlap with monogenic forms of the disease [@pgen.1002741-Voight1], and provided genetic links with correlated phenotypes [@pgen.1002741-Freathy1], [@pgen.1002741-Perry1].

The GWA studies of type 2 diabetes have not so far provided a greatly improved understanding of the clinical heterogeneity of the disease. Type 2 diabetes cases vary appreciably in their clinical characteristics, particularly age of diagnosis and body mass index (BMI). There is also a group of patients who may present with evidence of an autoimmune component to their diabetes, but who are not insulin dependent [@pgen.1002741-Tuomi1]. In contrast, the identification of the genetic component to monogenic forms of diabetes has often explained the clinical heterogeneity observed [@pgen.1002741-Pearson1].

Previous studies have provided some evidence of genetic heterogeneity between non-obese and obese type 2 diabetic cases [@pgen.1002741-Timpson1], [@pgen.1002741-Cauchi1], [@pgen.1002741-Cauchi2], [@pgen.1002741-Guey1]. For example, the variant with the strongest effect on type 2 diabetes risk, in *TCF7L2*, has a stronger effect in non-obese cases (odds ratio = 1.53 \[0.37--1.71\] compared to obese cases (OR = 1.21 \[1.09--1.35\]) [@pgen.1002741-Timpson1]. The effect of *FTO* variation on type 2 diabetes risk depends on how cases and controls are ascertained by BMI status, but this was expected given *FTO*\'s known primary effect on BMI. In the most recent GWA studies of type 2 diabetes [@pgen.1002741-Voight1], risk variants tended to have stronger effects in non-obese compared to obese individuals -- of 30 loci examined, 23 showed stronger associations in non-obese compared to obese individuals.

We designed the present study in an attempt to understand better the genetic heterogeneity of type 2 diabetes. Type 2 diabetes GWA studies tend to be enriched with cases with stronger family histories and lower average BMIs compared to community based studies. Nevertheless, there is a wide spectrum of BMI amongst type 2 diabetes cases used in GWA studies, with more cases being obese than lean. In this study we tested the hypothesis that we would identify new genetic variants by limiting the clinical heterogeneity of type 2 diabetes. By stratifying cases by their BMI status and performing separate GWA studies for each strata of BMI we identified two signals of association not previously reported in the largest GWA studies in Europeans [@pgen.1002741-Voight1], although one signal has been identified in a South Asian study [@pgen.1002741-Kooner1]. In addition we confirmed with additional data that the majority of known type 2 diabetes genetic associations have stronger effects in lean type 2 diabetic cases compared to obese cases.

Methods {#s2}
=======

Descriptions of all cases are available in [Table 1](#pgen-1002741-t001){ref-type="table"}, and combined with control details in [Tables S1](#pgen.1002741.s001){ref-type="supplementary-material"} and [S2](#pgen.1002741.s002){ref-type="supplementary-material"}. Our study was designed to limit the clinical heterogeneity of type 2 diabetes by stratification on BMI, whilst also using the largest sample sizes available:
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###### Patient characteristics for discovery and replication type 2 diabetes case samples.

![](pgen.1002741.t001){#pgen-1002741-t001-1}

                               Lean Patients   Obese Patients                                                                              
  --------------------------- --------------- ---------------- ----------------- ---------------- --------- ------------- ---------------- ----------------
  **GWA studies discovery**                                                                                                                
  DGI                               225           106/119        59.47 (10.57)     22.93 (1.51)      303       143/160      56.49 (9.90)     33.10 (2.52)
  WTCCC                             257            160/97             n/a          23.00 (1.54)     1,011      533/478          n/a          35.63 (4.98)
  FUSION                            123            78/45         53.67 (9.73)      23.22 (1.61)      529       265/264      53.62 (8.72)     34.00 (3.37)
  deCODE                            214            117/97        54.60 (14.90)     23.20 (1.78)      625       346/279     54.10 (11.20)     34.69 (4.38)
  KORA                              36             21/15         57.48 (11.92)     23.47 (1.33)      219       115/104      56.77 (9.82)     34.64 (4.07)
  DGDG                              185            99/86         44.30 (9.13)      22.72 (1.81)      \-          \-              \-               \-
  Rotterdam                         301           144/157             n/a          22.87 (1.58)      247       62/185           n/a          33.05 (3.02)
  Eurospan-MICROS                   \-               \-               \-                \-           22         15/7            n/a          34.30 (3.65)
  Eurospan-Orcades                  \-               \-               \-                \-           21         14/7            n/a          35.25 (4.52)
  Eurospan-ERF                      \-               \-               \-                \-           25         14/11           n/a          34.98 (3.80)
  Eurospan-Vis                      \-               \-               \-                \-           38         25/13           n/a          32.83 (2.74)
  FHS                               93             47/46              58              23.07          331       181/150         56.00            36.27
  ARIC                              111            52/59         47.90 (12.00)     23.06 (1.50)      358       174/178      51.40 (9.35)     34.95 (4.27)
  NHS                               567            0/100         57.68 (13.37)     22.67 (1.67)      394        0/100      56.01 (10.10)     33.88 (3.77)
  *Total*                         *2,112*                       *54.14 (11.66)*   *23.02 (1.59)*   *4,123*                 *54.91 (9.84)*   *34.43 (3.76)*
  **Replication**                                                                                                                          
  GoDarts                           263           151/112        56.83 (8.95)      22.97 (1.77)     1,735      950/785      54.8 (8.96)      35.94 (5.33)
  DGDG                             1,161          680/530        48.00 (10.02)     22.53 (1.51)     2,972    1,599/1,504   49.00 (11.12)     34.43 (4.36)
  Malmo CC                          477           291/186         59.2 (11.6)       22.9 (1.9)      1080       583/497      55.8 (10.8)      34.70 (4.30)
  ADDITION-Ely                      39             27/12         66.59 (5.20)      23.31 (1.57)      586       346/240      60.67 (7.65)     35.69 (4.78)
  EPIC-NDCCS                        941           544/397        63.35 (12.29)     22.96 (1.76)     2,329    1,208/1,121   58.01 (11.25)     35.04 (4.81)
  *Total*                         *2,881*                       *58.79 (9.61)*    *22.93 (1.7)*    *8,702*                 *55.66 (9.96)*   *35.16 (4.72)*

Eurospan represents a single cohort in the main text, however is split into its component studies in this table. There were too few lean cases in the Eurospan studies to include in meta-analysis. - = individuals not used. n/a = individuals used in analyses but data not available.

Study design---choice of strata {#s2a}
-------------------------------

To test the hypothesis that we would identify new variants associated with type 2 diabetes in different BMI strata, we used the following study design. We used two separate strata of type 2 diabetes cases defined by the two arbitrary, but well established, cut-offs for classifying people as overweight or obese. The first stratum consisted of non-overweight cases, here defined as "lean" (BMI\<25 kg/m^2^). The second strata consisted of obese cases (BMI≥30 kg/m^2^). For each stratum we used all controls, not selected on BMI to increase statistical power and provide a more robust estimate of the population allele frequency. We did not correct for BMI as BMI was not available in all controls. To check whether or not associations were being driven primarily by effects on BMI we assessed novel variants in an existing GWA studies of BMI using 123,865 individuals from the GIANT consortium [@pgen.1002741-Speliotes1]. Finally, we performed sensitivity analyses, confirming our findings by stratifying controls by BMI as well as cases.

Study design---choice of studies {#s2b}
--------------------------------

We chose to include the largest set of studies available. These studies differed in the proportion of total cases defined as lean (8.4--30.4%), the proportion of total cases defined as obese (21.2--77.8%, plus one GWA study, DGDG, that only selected non-obese cases). Some studies were specifically designed as case control studies and some as case-cohort studies, and we note that the extent of phenotyping performed to exclude autoimmune processes was different across studies, ranging from not requiring insulin treatment in the first year of diagnosis and GAD autoantibody negative, to general practitioner diagnosis of type 2 diabetes.

Descriptions of the participating studies are available in the most recent DIAGRAM manuscript [@pgen.1002741-Voight1], with summary statistics also presented in [Table 1](#pgen-1002741-t001){ref-type="table"} and in [Tables S1](#pgen.1002741.s001){ref-type="supplementary-material"} and [S2](#pgen.1002741.s002){ref-type="supplementary-material"}. The two discovery GWA study meta-analyses comprised 2112 lean type 2 diabetes cases or 4123 obese type 2 diabetes cases, compared against up to 54,412 controls. For a subset of SNPs available on the Metabochip (a custom Illumina iSelect SNP array that included the SNPs identified by GWA studies for several diseases and traits including type 2 diabetes loci) we included data from an additional 263 lean type 2 diabetes cases, 1735 obese type 2 diabetes cases, and 3691 controls from the GoDARTs study [@pgen.1002741-Zhou1].

GWA study methodology {#s2c}
---------------------

With the exception of the BMI-stratification of cases, the meta-analyses, individual study quality control, and analytical methods were the same as those recently reported [@pgen.1002741-Voight1]. A genomic control inflation factor was calculated for each study for each analysis, and their test statistics were adjusted accordingly. Inverse-variance fixed effect meta-analyses were performed on imputed SNP datasets, testing for an additive genetic effect. All single point effect estimates are given with their \[95% confidence intervals (CI)\]. Only autosomal SNPs with imputation quality scores \>0.5 and a minor allele frequency \>1% were included from each study. A SNP was excluded from the meta-analysed dataset if it was present in less than half of the studies. Given the use of two strata, we used a p-value threshold of 2.5×10^−8^ as the criterion for genome-wide significance.

Follow-up studies---replication of novel associations in lean and obese GWA studies {#s2d}
-----------------------------------------------------------------------------------

An additional 4 studies, totalling 2881 lean cases, 8702 obese cases, and 18957 controls were available for *de novo* genotyping of SNPs ([Table S2](#pgen.1002741.s002){ref-type="supplementary-material"}). For the DGDG replication, all polymorphisms were genotyped using the KASPar system (KBiosciences). For Malmo CC, ADDITION-Ely, and Norfolk Diabetes Case Control Study (NDCCS), Taqman assay genotyping was performed. For all four studies genotyping success rate was \>95%, the genotyping error rate was 0% based on re-genotyping of 384 individuals, and all SNPs were in Hardy-Weinberg equilibrium (*P*\>0.05). We re-performed the inverse-variance weighted meta-analysis for the replication SNPs using data from all the discovery and replication datasets.

Association of variants with BMI {#s2e}
--------------------------------

To test whether or not type 2 diabetes associations could be primarily driven by effects on BMI, we assessed the association of novel SNPs with BMI using data from the GIANT consortium consisting of 123,865 individuals.

Association of variants in case-only analyses {#s2f}
---------------------------------------------

There are two possible reasons why a variant may be associated with type 2 diabetes in a stratified sample compared to using all data. First, the variant may have a genuinely larger effect in that stratum compared to the overall sample. Second, chance will influence which SNPs are most strongly associated in different subsets of data. To distinguish between these two possibilities we performed a case only analysis in which we tested whether variants associated with lean or obese type 2 diabetes were also associated with BMI within type 2 diabetes cases. We analysed BMI as a quantitative trait in cases from the GWA studies and meta-analysed the summary statistics. If a variant is genuinely associated with type 2 diabetes with stronger effects in the lean stratum, for example, we would expect the risk allele to be associated with lower BMI within cases. This phenomenon was previously reported for the variant in *TCF7L2* [@pgen.1002741-Timpson1].

Continuous glycaemic measures {#s2g}
-----------------------------

SNP association statistics on glyacemic traits in healthy individuals were provided by the Meta-Analyses of Glucose and Insulin-related traits Consortium (MAGIC). Phenotypes available were fasting insulin (N = 38,238, fasting glucose (N = 46,186), beta-cell function (HOMA-B, N = 36,466), insulin resistance (HOMA-IR, N = 37,037), HbA~1C~ (N = 46,368) and 2 hour glucose (N = 15,234) after an oral glucose challenge. All traits are naturally log transformed, besides fasting glucose, 2 hour glucose and HbA1c. The studies and methodology for these GWA study data are described in their recent publications [@pgen.1002741-Dupuis1], [@pgen.1002741-Soranzo1], [@pgen.1002741-Saxena1] and available online at [www.magicinvestigators.org](http://www.magicinvestigators.org). We also had access to data from joint meta-analyses of SNP and SNPxBMI interaction on fasting glucose (N = 58,074), insulin (N = 51,570), and 2-hr glucose (N = 15,141), also provided by MAGIC (Manning *et al*, in press).

eQTL assessment {#s2h}
---------------

Identified SNPs were searched against a collected database of expression SNP (eQTL) results including a range of tissues [@pgen.1002741-Goring1], [@pgen.1002741-Idaghdour1], [@pgen.1002741-Heap1], [@pgen.1002741-Dixon1], [@pgen.1002741-Stranger1], [@pgen.1002741-Kwan1], [@pgen.1002741-Heinzen1], [@pgen.1002741-Zeller1], [@pgen.1002741-Emilsson1], [@pgen.1002741-Greenawalt1], [@pgen.1002741-Kompass1], [@pgen.1002741-Webster1], [@pgen.1002741-Schadt1], [@pgen.1002741-Innocenti1], [@pgen.1002741-Grundberg1], [@pgen.1002741-Ding1], [@pgen.1002741-Dimas1].

Testing the role of known SNPs in lean and obese individuals {#s2i}
------------------------------------------------------------

In addition to identifying new loci, we tested the impact of BMI stratification on SNPs previously identified as associated with type 2 diabetes. We calculated the individual SNP association statistics using the lean and obese meta-analyses described above.

To assess the effects of combining information from all known type 2 diabetes SNPs, we next used a single study, the GoDARTs [@pgen.1002741-Zhou1] study, independent from the discovery GWA studies. In GoDARTs there were a total of 263 lean type 2 diabetes cases, 1735 obese type 2 diabetes cases, and 3691 controls. Known SNPs (N = 36 on the metabochip) were defined as those reaching genome-wide significance in studies using samples of European descent (excluding *FTO* due to primary effect on BMI, and *DUSP9* not present on the chip) [@pgen.1002741-Voight1], [@pgen.1002741-Dupuis1], [@pgen.1002741-Qi1]. We also combined the 36 SNPs into a single allele count model. This analysis consisted of a logistic regression model comparing the count of an individual\'s type 2 diabetes risk alleles, against case-control status. Each risk allele count was weighted by the point estimate effect size of that SNP from the DIAGRAM meta-analysis [@pgen.1002741-Voight1]. We repeated this analysis using stratified controls (BMI\<25 kg/m^2^ versus lean cases and BMI≥30 kg/m^2^ versus obese cases) instead of all controls. Finally, individuals were binned into quintiles based on their weighted allele score and per-quintile odds ratios calculated.

Results {#s3}
=======

Genome-wide association in lean type 2 diabetic individuals {#s3a}
-----------------------------------------------------------

Three independent association signals reached *P*\<2.5×10^−8^ in the lean case genome wide meta-analysis ([Table 2](#pgen-1002741-t002){ref-type="table"}). Two represented previously reported loci - *TCF7L2* (OR = 1.58 \[1.47--1.68\], *P* = 2×10^−40^) and *CDKAL1* (OR = 1.26 \[1.17--1.35\], *P* = 7×10^−10^). One novel locus reached genome-wide significance, lead SNP positioned ∼25 kb from the *HLA-DQA2* gene (OR = 1.3 \[1.19--1.42\], *P* = 1×10^−8^). Three further independent signals reached *P*\<5×10^−7^, two of which were previously identified (SNPs in or near *ADCY5*, OR = 1.25 \[1.15--1.35\] *P* = 6×10^−8^, and *SLC30A8*, OR = 1.23 \[1.15--1.33\] *P* = 4×10^−8^) and one of which was novel (SNPs in *LAMA1*, OR = 1.22 \[1.12--1.30\] *P* = 1×10^−7^). Rs numbers are given in [Table 2](#pgen-1002741-t002){ref-type="table"}.

10.1371/journal.pgen.1002741.t002

###### Highest-ranked independent signals in the lean and obese case GWA studies.
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                                             Discovery        Replication    Combined                                                                                                                             
  ------------ ------------ --- ------ --------------------- ------------- ------------ --------------------- ---------- ------------ --------------------- ------- ------------ ---------- --------------------- ------------
  rs7903146      *TCF7L2*    t   0.29   1.58 \[1.47--1.68\]    2.00E−40     2375/55249   1.26 \[1.2--1.32\]    4.40E−21   5858/58103           n/a            n/a       n/a         n/a              n/a              n/a
  rs7766070      *CDKAL1*    a   0.27   1.26 \[1.17--1.35\]    7.30E−10     2112/51558   1.21 \[1.14--1.28\]   5.80E−11   5858/58103           n/a            n/a       n/a         n/a              n/a              n/a
  rs3916765     *HLA-DQA2*   a   0.12   1.3 \[1.19--1.42\]     1.20E−08     2375/55249   1.07 \[1.00--1.15\]     0.04     5858/58103   0.96 \[0.81--1.13\]   0.62    1161/3960    1.00E−06   1.21 \[1.12--1.31\]   3536/59209
  rs3802177     *SLC30A8*    g   0.68   1.23 \[1.15--1.33\]    3.80E−08     2082/50879   1.12 \[1.06--1.19\]   5.03E−05   5858/58103           n/a            n/a       n/a         n/a              n/a              n/a
  rs11708067     *ADCY5*     a   0.78   1.25 \[1.15--1.35\]    5.70E−08     2375/55249   1.07 \[1.01--1.14\]     0.01     5858/58103           n/a            n/a       n/a         n/a              n/a              n/a
  rs8090011      *LAMA1*     g   0.38   1.22 \[1.12--1.3\]     1.00E−07     2112/51558   1.02 \[0.96--1.08\]     0.5      5858/58103   1.09 \[1.03--1.15\]   0.003   2881/18957   8.40E−09   1.13 \[1.09--1.18\]   4993/70515

  Obese Analysis                                 Obese            Lean       Obese                                                                                                                             
  ---------------- ---------- --- ------ --------------------- ---------- ------------ --------------------- ---------- ------------ --------------------- ------ ----------- ---------- --------------------- ------------
  rs7903146         *TCF7L2*   t   0.29   1.26 \[1.2--1.32\]    4.40E−21   5858/58103   1.58 \[1.47--1.68\]   2.00E−40   2375/55249           n/a           n/a       n/a        n/a              n/a              n/a
  rs9939609          *FTO*     a   0.4    1.25 \[1.19--1.3\]    1.10E−20   5858/58103   0.95\[0.89--1.02\]      0.16     2375/55249           n/a           n/a       n/a        n/a              n/a              n/a
  rs7766070         *CDKAL1*   a   0.27   1.21 \[1.14--1.28\]   5.80E−11   4123/54412   1.26 \[1.17--1.35\]   7.30E−10   2375/55249           n/a           n/a       n/a        n/a              n/a              n/a
  rs5015480          *HHEX*    c   0.57   1.18 \[1.11--1.23\]   1.90E−09   4123/54412   1.17\[1.09--1.25\]    6.15E−06   2375/55249           n/a           n/a       n/a        n/a              n/a              n/a
  rs4402960         *IG2BP2*   t   0.31   1.15 \[1.1--1.21\]    2.50E−09   5858/58103   1.16\[1.08--1.24\]    1.53E−05   2375/55249           n/a           n/a       n/a        n/a              n/a              n/a
  rs6567160          *MC4R*    c   0.23   1.15 \[1.09--1.2\]    1.80E−07   5858/58103   1.07\[0.99--1.15\]      0.07     2375/55249           n/a           n/a       n/a        n/a              n/a              n/a
  rs7178572         *HMG20A*   g   0.7    1.14 \[1.09--1.19\]   2.10E−07   5858/58103   1.09\[1.02--1.16\]      0.01     2375/55249    1.09 \[1--1.16\]     0.04   2972/3960   1.30E−08   1.11 \[1.07--1.15\]   8583/62063
  rs16896390        *ANKS1A*   c   0.91   1.3 \[1.18--1.43\]    4.70E−07   4123/54412   1.14\[1.00--1.29\]      0.04     2375/55249   0.97 \[0.89--1.06\]   0.55   4707/7651    0.002     1.11 \[1.04--1.19\]   8583/62063

SNPs mapped to '+' strand, genome build 36. Independence based on hapmap r^2^\<0.05. Study directions show directional consistency of effect size estimates within the individual cohorts meta-analysed.

Genome-wide association in obese type 2 diabetic individuals {#s3b}
------------------------------------------------------------

In the obese case genome wide meta-analysis, five signals reached genome-wide significance ([Table 2](#pgen-1002741-t002){ref-type="table"}), all in or near known loci *TCF7L2*, *FTO*, *CDKAL1*, *HHEX*, and *IGF2BP2*. A further three signals reached *P*\<5×10^−7^; SNPs in or near the *MC4R* gene (previously associated with BMI), and two other signals; in *HMG20A* (previously reported in South Asians -OR = 1.14 \[1.09--1.19\] *P* = 2×10^−7^) and in *ANKS1A* (OR = 1.3 \[1.18--1.43\] *P* = 5×10^−7^).

Follow-up of putative novel signals {#s3c}
-----------------------------------

We sought to replicate the signals reaching *P*\<5×10^−7^ not previously reported in Europeans. SNPs representing the *LAMA1* (rs8090011), *HLA-DQA2* (rs3916765), *HMG20A* (rs7178572), and *ANKS1A* (rs16896390) signals were genotyped in up to 2,881 lean cases, 8,702 obese cases and 18,957 control individuals. Combined discovery and follow-up association statistics for these SNPs are shown in [Table 2](#pgen-1002741-t002){ref-type="table"}. In the lean case analysis, the *LAMA1* variant was associated with type 2 diabetes (combined *P* = 8.4×10^−9^, OR = 1.13 \[1.09--1.18\], total lean cases N = 4,993, controls = 70,515) compared to an OR = 1.03 \[1.00--1.06\] in the obese case analysis ([Figure 1](#pgen-1002741-g001){ref-type="fig"} and [Figure 2](#pgen-1002741-g002){ref-type="fig"}). In the obese case analysis, the *HMG20A* signal was associated with type 2 diabetes (combined *P* = 1.3×10^−8^, OR = 1.11 \[1.07--1.15\], total obese cases N = 8,583, controls = 62,063) compared to an OR = 1.09 \[1.02--1.17\], *P* = 0.015, in the lean analysis ([Figure 3](#pgen-1002741-g003){ref-type="fig"} and [Figure 4](#pgen-1002741-g004){ref-type="fig"}). In previously published studies including 8,130 cases not stratified by BMI [@pgen.1002741-Voight1], the *LAMA1* and *HMG20A* variants reached only nominal levels of significance of *P* = 0.002 (OR = 1.07 \[1.03--1.12\]) and *P* = 0.003, OR = 1.07 \[1.02--1.12\] respectively (both in the same directions as reported here).

![Test statistics for LAMA1 association in lean and obese cases versus all controls.](pgen.1002741.g001){#pgen-1002741-g001}

![Regional association plot for the *LAMA1* gene in lean type 2 diabetes samples.](pgen.1002741.g002){#pgen-1002741-g002}

![Test statistics for *HMG20A* association in lean and obese cases versus all controls.](pgen.1002741.g003){#pgen-1002741-g003}

![Regional association plot for the *HMG20A* gene in obese type 2 diabetes samples.](pgen.1002741.g004){#pgen-1002741-g004}

Considering a random-effects model [@pgen.1002741-Han1] for both *LAMA1* and *HMG20A* signals gave similar evidence for association (*LAMA1* lean analysis: *P* = 5×10^−10^, obese analysis: *P* = 0.02; *HMG20A* lean analysis: *P* = 0.04, obese analysis: *P* = 2.7×10^−8^). Evidence for association at the *HLA-DQA2* and *ANKS1A* signals was reduced when follow-up data were included.

Association of variants with BMI {#s3d}
--------------------------------

We next attempted to understand further the associations between SNPs in the *LAMA1* and *HMG20A* loci and lean and obese type 2 diabetes cases respectively. Our study design, together with the associations between the *FTO* and *MC4R* variants in the obese strata, suggested that variants that primarily operate through BMI could drive our newly identified associations. We therefore assessed the two signals in the existing GWA studies of BMI performed by the GIANT study and consisting of 123,865 individuals [@pgen.1002741-Speliotes1]. The *LAMA1* SNP was not associated with BMI (*P* = 0.19) whilst the type 2 diabetes risk allele at the *HMG20A* SNP was nominally associated with increased BMI (*P* = 0.02).

Association of variants with BMI within cases only {#s3e}
--------------------------------------------------

If the associations at the *LAMA1* and *HMG20A* loci are genuinely stronger in one strata of diabetic cases compared to the other, we should observe an association of those variants with BMI within cases only. This phenomenon has previously been reported for the variants in *TCF7L2\[14\]*. The *LAMA1* type 2 diabetes risk allele was associated with lower BMI within cases alone (*P* = 2×10^−6^ when analysing BMI as a quantitative trait in 26,366 cases), a result consistent with its association being stronger in the lean case analysis. The *HMG20A* risk allele showed no evidence of association (*P*\>0.05).

Association of variants with continuous glycaemic measures {#s3f}
----------------------------------------------------------

Next we used data from MAGIC to assess potential roles of variants in normal glycaemia. The SNP representing the novel *LAMA1* association showed no association with fasting glucose (*P* = 0.48, beta(se) = 0.0027(0.004) N = 46,186), fasting insulin (*P* = 0.87, beta(se) = 0.0006(0.004) N = 38,238), HbA~1C~ (*P* = 0.19, beta(se) = 0.005(0.004) N = 46,368), 2-hour glucose response (*P* = 0.43, beta(se) = −0.016(0.02), N = 15,234), or any of the SNP×BMI-interaction models. However, *LAMA1* isn\'t unique amongst type 2 diabetes loci in showing no effect on glycemic traits in the MAGIC study.

The *HMG20A* diabetes risk allele was associated with higher fasting glucose (*P* = 0.04, beta(se) = 0.008(0.004), N = 46,186), higher HbA1C (*P* = 0.002, beta(se) = 0.01(0.004), N = 46,368) and higher fasting glucose after accounting for BMI and SNPxBMI interaction (*P* = 0.008, N = 58,074).

Association of variants with *cis* gene expression levels {#s3g}
---------------------------------------------------------

In an attempt to gain further insight into likely functional genes in the *LAMA1* and *HMG20A* loci, we tested the lead SNPs at for association in a number of eQTL datasets. Tissues tested included various blood, brain, liver and fat samples (see [Methods](#s2){ref-type="sec"}). Only '*cis*' associations were considered (eQTL effects on a transcript within 1 Mb of the signal SNPs). The rs7178572 SNP in the *HMG20A* region was significantly associated with mRNA expression levels of *HMG20A* in the liver (*P* = 4×10^−5^), supported by two separate expression probes, and was the strongest known regional SNP for both the liver eQTL and type 2 diabetes. No other study-wide significant results were observed (N = 14 tissues, 24 datasets/analyses).

Evidence that genetic variants associated with type 2 diabetes have different effects between lean and obese cases {#s3h}
------------------------------------------------------------------------------------------------------------------

For each of 36 published type 2 diabetes loci (identified in European studies and available on the metabochip) we compared the effect sizes between the lean and obese GWA study meta-analyses ([Table 3](#pgen-1002741-t003){ref-type="table"}). Among the 36 independent variants, 29 had a larger point estimate odds ratio in the lean analysis compared to the obese analysis (binomial test of 29/36 versus 50% under the null hypothesis of no difference, *P* = 0.0002). We next assessed the combined effect of these SNPs in a case control study independent of the GWA studies - GoDARTs ([Figure 5](#pgen-1002741-g005){ref-type="fig"}). In the lean stratum, we observed a weighted per-risk allele OR = 1.13 \[1.10--1.17\], *P* = 3.2×10^−14^. This was larger than the same model fitted in the obese strata where the OR = 1.06 \[1.05--1.08\], *P* = 2.2×10^−16^. Results were very similar when stratifying the controls as well as the cases by BMI: lean weighted per risk-allele OR = 1.13 \[1.09--1.17\]; obese weighted per risk-allele OR = 1.08 \[1.05--1.10\] (heterogeneity of odds ratios *P* = 0.036). We also observed a difference between lean and obese cases when removing controls and fitting a regression model of lean cases vs obese cases (P = 0.0001). None of these 36 variants were associated with BMI in 28,000--32,000 individuals from GIANT [@pgen.1002741-Voight1], [@pgen.1002741-Dupuis1].

![Risk allele distribution for known type 2 diabetes SNPs in GoDARTs.\
Plot shows number of type 2 diabetes risk alleles carried by the 263 lean type 2 diabetes cases, 1,735 obese type 2 diabetes cases and 3,691 controls from the GoDARTs study.](pgen.1002741.g005){#pgen-1002741-g005}

10.1371/journal.pgen.1002741.t003

###### Association statistics for known European type 2 diabetes loci in the lean and obese GWA studies strata.

![](pgen.1002741.t003){#pgen-1002741-t003-3}

                                         Lean T2D Cases N = 2112 vs all controls   Obese T2D Cases N = 4123 vs all controls                       
  ------------ --------------- ---- --- ----------------------------------------- ------------------------------------------ -------------------- ----------
  rs7903146       *TCF7L2*      10   T             1.58\[1.47--1.68\]                              2.0E−40                    1.26\[1.20--1.32\]   4.40E−21
  rs11708067       *ADCY5*      3    A             1.25\[1.15--1.35\]                              5.7E−08                    1.07\[1.01--1.14\]     0.01
  rs10923931      *NOTCH2*      1    T             1.22\[1.11--1.35\]                              0.00007                    1.06\[0.98--1.13\]     0.14
  rs13266634      *SLC30A8*     8    C             1.24\[1.15--1.34\]                              5.1E−08                    1.12\[1.06--1.19\]   0.00005
  rs2237892        *KCNQ1*      11   C             1.29\[1.12--1.48\]                               0.0003                    1.11\[1.01--1.22\]     0.02
  rs10010131       *WFS1*       4    G             1.14\[1.07--1.22\]                              0.00005                    1.07\[1.02--1.12\]    0.004
  rs10811661     *CDKNA/2B*     9    T             1.22\[1.12--1.33\]                              0.000007                   1.12\[1.05--1.19\]    0.0002
  rs5215          *KCNJ11*      11   C             1.15\[1.08--1.23\]                              0.00002                    1.08\[1.03--1.13\]    0.0007
  rs4457053        *ZBED3*      5    G             1.14\[1.05--1.24\]                               0.002                     1.06\[1.00--1.12\]     0.04
  rs340874         *PROX1*      1    C             1.12\[1.05--1.19\]                               0.0008                    1.06\[1.01--1.11\]     0.02
  rs7957197        *HNF1A*      12   T             1.07\[0.99--1.16\]                                0.07                     1.01\[0.96--1.07\]     0.69
  rs243021        *BCL11A*      2    A             1.12\[1.05--1.20\]                               0.0006                    1.07\[1.01--1.12\]     0.01
  rs896854       *TP53INP1*     8    T             1.02\[0.96--1.09\]                                0.44                     1.07\[1.03--1.12\]    0.002
  rs757210         *HNF1B*      17   T             1.17\[1.05--1.29\]                               0.003                     1.09\[1.02--1.17\]     0.02
  rs7578597        *THADA*      2    T             1.20\[1.08--1.33\]                               0.0008                    1.12\[1.04--1.20\]    0.004
  rs1111875        *HHEX*       10   C             1.18\[1.10--1.25\]                              5.3E−07                    1.13\[1.08--1.18\]   6.4E−08
  rs972283         *KLF14*      7    G             1.13\[1.06--1.20\]                               0.0002                    1.09\[1.04--1.14\]    0.0003
  rs7593730     *RBMS1/ITGB6*   2    C             1.12\[1.03--1.22\]                               0.005                     1.07\[1.00--1.14\]     0.03
  rs7754840       *CDKAL1*      6    C             1.19\[1.11--1.27\]                              3.80E−07                   1.14\[1.09--1.20\]   2.0E−08
  rs4607103       *ADAMTS9*     3    C             1.03\[0.95--1.11\]                                0.47                     1.07\[1.01--1.13\]     0.01
  rs1531343        *HMGA2*      12   C             1.13\[1.01--1.27\]                                0.03                     1.20\[1.10--1.31\]   0.00003
  rs7961581     *TSPAN8,LGR5*   12   C             1.17\[1.08--1.26\]                              0.00007                    1.13\[1.06--1.20\]   0.00007
  rs8042680        *PRC1*       15   A             1.07\[1.00--1.14\]                                0.05                     1.04\[0.99--1.09\]     0.10
  rs11634397      *ZFAND6*      15   G             1.08\[1.01--1.16\]                                0.03                     1.05\[1.00--1.10\]     0.04
  rs7578326        *IRS1*       2    A             1.10\[1.03--1.18\]                               0.008                     1.07\[1.02--1.13\]    0.006
  rs1552224       *CENTD2*      11   A             1.05\[0.96--1.14\]                                0.27                     1.08\[1.02--1.15\]     0.01
  rs1801282        *PPARg*      3    C             1.14\[1.04--1.26\]                               0.008                     1.11\[1.04--1.18\]    0.003
  rs12779790      *CAMK1D*      10   G             1.12\[1.03--1.22\]                               0.009                     1.09\[1.02--1.16\]    0.008
  rs864745         *JAZF1*      7    T             1.09\[1.03--1.16\]                               0.006                     1.08\[1.03--1.12\]    0.001
  rs780094         *GCKR*       2    C             1.04\[0.98--1.11\]                                0.19                     1.03\[0.98--1.08\]     0.22
  rs13292136       *TLE4*       9    C             1.15\[1.00--1.31\]                                0.04                     1.12\[1.00--1.24\]     0.04
  rs231362         *KCNQ1*      11   G             1.09\[1.02--1.17\]                                0.01                     1.08\[1.03--1.14\]    0.003
  rs4607517         *GCK*       7    A             1.03\[0.94--1.12\]                                0.55                     1.04\[0.98--1.10\]     0.20
  rs1470579       *IGF2BP2*     3    C             1.15\[1.07--1.23\]                              0.00009                    1.16\[1.10--1.23\]   6.4E−08
  rs10830963      *MTNR1B*      11   G             1.11\[1.03--1.20\]                               0.007                     1.10\[1.04--1.16\]    0.0005
  rs2191349     *DGKB/TME195*   7    T             1.03\[0.97--1.10\]                                0.38                     1.04\[0.99--1.08\]     0.13

KCNQ1 appears twice as it has two independent signals confirmed through conditional analysis.

We next divided the case/control samples into risk quintiles, based on the number of risk alleles they carry, weighted by the relative effect sizes of those alleles from the larger DIAGRAM meta-analysis. The risk of being in each quintile relative to the median quintile is shown in [Figure 6](#pgen-1002741-g006){ref-type="fig"}. For the lean group, we observed an OR = 2.1 \[1.47--3.01\] for the quintile of individuals carrying the most risk alleles compared to the middle quintile. This effect was larger than that in the obese group where the equivalent OR = 1.37 \[1.15--1.64\].

![Relative risk for type 2 diabetes depending on risk allele quintile, split by lean and obese BMI.\
Individuals binned into quintiles based on risk-allele count of known SNPs, weighted by effect size of SNP. Risk estimates relative to median quintile. Total sample size across all quintiles is 263 lean type 2 diabetes cases, 1735 obese type 2 diabetes cases and 3691 controls from the GoDARTs study.](pgen.1002741.g006){#pgen-1002741-g006}

Discussion {#s4}
==========

We have confirmed our hypothesis that it is possible to identify genetic associations in previously tested samples by constraining the phenotypic heterogeneity of disease cases. By stratifying type 2 diabetes into two well accepted definitions of lean and obese cases, we identified and replicated one locus in each BMI stratum, each previously unreported in European studies: a signal in the *LAMA1* gene in the lean stratum and a signal in the *HMG20A* gene in the obese stratum. Lack of evidence for association with BMI for these two signals in 123,000 individuals [@pgen.1002741-Speliotes1] argues that these associations are not driven by a primary association with BMI.

There are two reasons why previously undetected genetic associations may be observed in stratified data. First chance, in this context "sampling error", may occur -- new signals may reach statistical thresholds in subsets of data due to a combination of real association and chance. Second, the signal may represent genuine heterogeneity. The enrichment of the *LAMA1* signal in lean type 2 diabetes cases compared to obese cases is likely to be a real effect but the enrichment of the *HMG20A* signal in obese cases is more likely to be due to chance. Whilst we observed some regression to the mean (or "winner\'s curse") for the *LAMA1* signal, the effects remained different in lean compared to obese cases in the replication samples alone ([Figure 1](#pgen-1002741-g001){ref-type="fig"}). In addition, the *LAMA1* type 2 diabetes risk allele was associated with lower BMI within cases alone (*P* = 2×10^−6^ when testing BMI as a quantitative trait in cases) -- a similar result was previously reported for the *TCF7L2* risk allele [@pgen.1002741-Cauchi2]. In contrast there is no evidence that the *HMG20A* signal is stronger in obese replication strata compared to lean replication strata ([Figure 3](#pgen-1002741-g003){ref-type="fig"}) and there was no association with increased BMI within cases alone (*P*\>0.05 when testing BMI as a quantitative trait in cases).

The *LAMA1* signal falls in a recombination block within the *LAMA1* gene ([Figure 2](#pgen-1002741-g002){ref-type="fig"}), with the lead SNP positioned within intron 61. Searching for correlated SNPs (r^2^\>0.5) using 1000 Genomes Project data identified only additional intronic SNPs. Previous cell biology studies support a role for *LAMA1*, encoding laminin-1, in diabetes etiology - inhibition of *LAMA1* expression reduced glucose-stimulated secretion in INS1E cells [@pgen.1002741-Antinozzi1]. Several studies observed the beneficial effects of laminin-1, and extracellular matrix (highly enriched with laminin-1) preparations on pancreatic islet development and function [@pgen.1002741-Jiang1], [@pgen.1002741-Vasir1], [@pgen.1002741-BonnerWeir1], [@pgen.1002741-Gao1], [@pgen.1002741-Jiang2], [@pgen.1002741-Jiang3]. Laminin-1 is expressed in intra-islet capillaries [@pgen.1002741-Geutskens1] and a role for laminin receptor 1 was proposed in angiogenesis [@pgen.1002741-Hu1].

The confidence in the *HMG20A* association is enhanced by several lines of evidence from other studies. The *HMG20A* signal was previously identified in a GWA study of South Asian individuals [@pgen.1002741-Kooner1] and was nominally associated with fasting glucose (*P* = 0.04, N = 46,186) and HbA1C (*P* = 0.002, N = 46,368) in non-diabetic individuals analysed by the MAGIC consortium. The association with fasting glucose became stronger when adjusting for BMI in an interaction model (*P* = 0.008).

We initially discovered a genome-wide significant signal near the *HLA-DQA2* locus, which subsequently failed to replicate (rs3916765, *P* = 1×10^−6^). This variant is not in the same gene or in linkage disequilibrium with previously reported associations between *HLA* loci and type 2 diabetes [@pgen.1002741-Voight1], [@pgen.1002741-Williams1]. Concerned with the prospect of this association being due to auto-immune diabetes case admixture, we assessed the association of the strongest known type 1 diabetes signals in our lean meta-analysis. None of these showed any significant evidence of association -- including the lead signals from the WTCCC type 1 diabetes study in the HLA region (rs3129941, *P* = 0.08), or near the *INS* (rs3842748, *P* = 0.64) or *PTPN22* (rs2476601, *P* = 0.38) genes.

This study has provided the most robust evidence to date that lean type 2 diabetic cases are likely to carry a disproportionately high load of known type 2 diabetes risk alleles. More than 80% (29/36) of type 2 diabetes variants established in Europeans had stronger effects in lean compared to obese cases and the odds ratio for the 20% of lean cases carrying the most risk alleles was more than twice that of the 20% of obese cases carrying the most risk alleles. The corollary of these findings is that obese cases on average carry a disproportionately low load of confirmed type 2 diabetes risk variants, but their diabetes risk will likely be more heavily influenced by their genetic and environmental predisposition to gaining weight in adulthood.

Despite this enrichment of stronger effects in lean versus obese cases, analyses focused only on lean cases is not a more powerful study design compared to using all cases. For each of the known loci tested, the power gained by increased effect sizes is easily offset by the reduced power of having a case sample size of ∼25%. Nevertheless our data indicate that, given limited resources, recruitment strategies that target leaner type 2 diabetes cases will have more power than those that target a similar number of cases but without enrichment for lower BMI.

There are several limitations to our study. First, the use of an unstratified control group made testing the significance of differences between lean and obese cases difficult in the context of a genome wide meta-analysis. However, several lines of evidence support our conclusions that lean individuals are enriched for known type 2 diabetes genetic effects. This evidence includes: the very large differences between the upper and lower 95% confidence intervals of the weighted per allele effects in lean and obese, the consistency of the weighted per allele results when stratifying controls as well as cases, and the 80/20 proportion of SNPs showing stronger effects in lean compared to obese individuals respectively. Second, after stratifying by BMI, we did not use other criteria to reduce the clinical heterogeneity of type 2 diabetes. Of note, cases within the BMI strata differed appreciably in their age at diagnosis and the degree to which autoimmune or monogenic diabetes had been excluded. Instead, having stratified by BMI, we opted to use the largest available sample sizes. It is possible that a small number of monogenic or autoimmune forms of diabetes amongst our cases could have reduced our power to detect novel variants. Further studies may help refine how known and novel diabetes signals operate in more clinically homogenous settings. Finally, known type 2 diabetes signals are likely to account for only a small fraction of all risk variants that exist in the genome and any inferences we make are limited to the known signals.

In conclusion, we report associations with the *LAMA1* and *HMG20A* (not previously associated at genome-wide significance in Europeans) gene regions with type 2 diabetes risk. We have demonstrated that lean diabetic cases are enriched for known type 2 diabetes risk alleles compared to obese cases. This enrichment is consistent with the observation that many of the variants with the strongest effects on diabetes are associated with reduced beta cell function [@pgen.1002741-Voight1]. At the opposite end of the spectrum, obese cases presumably need fewer diabetes risk variants to push them towards diabetes, as they are already under strain from the physiological impact of obesity and insulin resistance. These data suggest a disease model where type 2 diabetes cases lie across a continuous distribution with regards to genetic/environmental risk, and beta-cell dysfunction versus insulin resistance aetiologies.
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